World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders

AIM This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (published in 2002, revised in 2008). METHOD A consensus panel of 33 international experts representing 22 countries developed recommendations based on efficacy and acceptability of available treatments. In total, 1007 RCTs for the treatment of these disorders in adults, adolescents, and children with medications, psychotherapy and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medications. RESULT This paper, Part I, contains recommendations for the treatment of panic disorder/agoraphobia (PDA), generalised anxiety disorder (GAD), social anxiety disorder (SAD), specific phobias, mixed anxiety disorders in children and adolescents, separation anxiety and selective mutism. Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line medications. Cognitive behavioural therapy (CBT) is the first-line psychotherapy for anxiety disorders. The expert panel also made recommendations for patients not responding to standard treatments and recommendations against interventions with insufficient evidence. CONCLUSION It is the goal of this initiative to provide treatment guidance for these disorders that has validity throughout the world.

[1]  D. Wedekind,et al.  Internet psychotherapeutic interventions for anxiety disorders – a critical evaluation , 2022, BMC Psychiatry.

[2]  M. Beutel,et al.  The German Guidelines for the treatment of anxiety disorders: first revision , 2021, European Archives of Psychiatry and Clinical Neuroscience.

[3]  D. Baldwin Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. , 2021, Addiction.

[4]  D. Baldwin,et al.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively , 2021, CNS Drugs.

[5]  B. Bandelow The myth that psychotherapy is more effective than pharmacotherapy in anxiety disorders , 2021, European Neuropsychopharmacology.

[6]  R. Shader,et al.  Benzodiazepines: it's time to return to the evidence , 2020, The British Journal of Psychiatry.

[7]  Alyssa M. Peckham,et al.  Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update , 2020, Drugs.

[8]  Marian Buhociu,et al.  Not what the doctor ordered: Motivations for nonmedical prescription drug use among people who use illegal drugs. , 2020, The International journal on drug policy.

[9]  D. Caldirola,et al.  Relapse prevention in panic disorder with pharmacotherapy: where are we now? , 2020, Expert opinion on pharmacotherapy.

[10]  K. Domschke,et al.  A neurobiological framework of separation anxiety and related phenotypes , 2020, European Neuropsychopharmacology.

[11]  S. Kellett,et al.  The dose-response effect in routinely delivered psychological therapies: A systematic review , 2020, Psychotherapy research : journal of the Society for Psychotherapy Research.

[12]  N. Dreyer,et al.  Trial designs using real‐world data: The changing landscape of the regulatory approval process , 2019, Pharmacoepidemiology and drug safety.

[13]  N. Singewald,et al.  Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. , 2019, Pharmacology & therapeutics.

[14]  Kuan-Chia Lin,et al.  Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. , 2019, Journal of psychiatric research.

[15]  R. Blashfield,et al.  Anxiety in Children with Selective Mutism: A Meta-analysis , 2019, Child Psychiatry & Human Development.

[16]  J. Krystal,et al.  Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment , 2019, Journal of psychopharmacology.

[17]  M. Mula,et al.  Treatment of psychoses in patients with epilepsy: an update , 2019, Therapeutic advances in psychopharmacology.

[18]  Mean age and gender distribution of patients with major mental disorders participating in clinical trials , 2019, European Archives of Psychiatry and Clinical Neuroscience.

[19]  H. Möller,et al.  WFSBP guidelines on how to grade treatment evidence for clinical guideline development , 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[20]  W. Rief,et al.  It can’t hurt, right? Adverse effects of psychotherapy in patients with depression , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[21]  P. Cuijpers,et al.  Efficacy and acceptability of psychological interventions for social anxiety disorder in children and adolescents: a meta-analysis of randomized controlled trials , 2018, European Child & Adolescent Psychiatry.

[22]  J. Kornhuber,et al.  Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis , 2018, JAMA psychiatry.

[23]  S. Hofmann,et al.  Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review , 2018, Expert opinion on pharmacotherapy.

[24]  D. Wedekind,et al.  Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies , 2018, The British Journal of Psychiatry.

[25]  R. Kessler,et al.  Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries , 2018, Depression and anxiety.

[26]  E. Foa,et al.  Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial , 2018, JAMA.

[27]  F. Schneier,et al.  A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder , 2017, Depression and anxiety.

[28]  A. Young,et al.  British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017 , 2017, Journal of psychopharmacology.

[29]  D. Nutt,et al.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[30]  F. Verhulst,et al.  The Age of Onset of Anxiety Disorders , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[31]  M. Lapeyre-Mestre,et al.  Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. , 2016, Therapie.

[32]  S. Tsai,et al.  Treatment-resistant panic disorder: clinical significance, concept and management , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  M. Bloch,et al.  Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.

[34]  D. Nutt,et al.  Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[35]  P. Salkovskis,et al.  A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. , 2016, Health technology assessment.

[36]  H. Simpson,et al.  Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive‐compulsive disorder , 2016, World psychiatry : official journal of the World Psychiatric Association.

[37]  K. Manassis,et al.  The use of medication in selective mutism: a systematic review , 2016, European Child & Adolescent Psychiatry.

[38]  S. Hollon,et al.  Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials , 2015, PloS one.

[39]  W. Naja,et al.  Pregabalin dependence: a case report. , 2015, Current drug safety.

[40]  P. Cuijpers,et al.  Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.

[41]  Gavin Andrews,et al.  Treatment-as-usual (TAU) is anything but usual: a meta-analysis of CBT versus TAU for anxiety and depression. , 2015, Journal of affective disorders.

[42]  D M Caldwell,et al.  Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta‐analysis , 2014, Acta psychiatrica Scandinavica.

[43]  D. Kupfer,et al.  A proposal for an updated neuropsychopharmacological nomenclature , 2014, European Neuropsychopharmacology.

[44]  A. Ehlers,et al.  A randomized controlled trial of 7-day intensive and standard weekly cognitive therapy for PTSD and emotion-focused supportive therapy. , 2014, The American journal of psychiatry.

[45]  C. Dennis,et al.  Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis , 2014, BMJ : British Medical Journal.

[46]  M. Stein,et al.  A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. , 2014, The American journal of psychiatry.

[47]  R. Shavitt,et al.  Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. , 2013, Journal of psychiatric research.

[48]  Christopher W. Jones,et al.  Non-publication of large randomized clinical trials: cross sectional analysis , 2013, BMJ.

[49]  C. Cooper,et al.  The relationship between depression, anxiety and cardiovascular disease: findings from the Hertfordshire Cohort Study. , 2013, Journal of affective disorders.

[50]  J. Hilden,et al.  Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors , 2013, Canadian Medical Association Journal.

[51]  C. Schönfeldt-Lecuona,et al.  Pregabalin abuse and dependence in Germany: results from a database query , 2013, European Journal of Clinical Pharmacology.

[52]  R. Kessler,et al.  Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States , 2012, International journal of methods in psychiatric research.

[53]  J. Olesen,et al.  The economic cost of brain disorders in Europe , 2012, European journal of neurology.

[54]  R. Dishman,et al.  Feasibility of Exercise Training for the Short-Term Treatment of Generalized Anxiety Disorder: A Randomized Controlled Trial , 2011, Psychotherapy and Psychosomatics.

[55]  Anders Sundström,et al.  A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system , 2010, European Journal of Clinical Pharmacology.

[56]  Dan J Stein,et al.  How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database , 2009, Human psychopharmacology.

[57]  J. Carlson,et al.  Efficacy of cognitive‐behavioral and pharmacological treatments for children with social anxiety , 2008, Depression and anxiety.

[58]  Jean-Philippe Laurenceau,et al.  Anxiety characteristics independently and prospectively predict myocardial infarction in men the unique contribution of anxiety among psychologic factors. , 2008, Journal of the American College of Cardiology.

[59]  D. Nutt,et al.  Uncritical positive regard? Issues in the efficacy and safety of psychotherapy , 2008, Journal of psychopharmacology.

[60]  Hans-Jürgen Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[61]  N. Frasure-smith,et al.  Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. , 2008, Archives of general psychiatry.

[62]  J. Mann,et al.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. , 2007, The American journal of psychiatry.

[63]  Dan J Stein,et al.  Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo , 2007, Pharmacopsychiatry.

[64]  G. Rubio,et al.  Generalized anxiety disorder: a 40‐year follow‐up study , 2007, Acta psychiatrica Scandinavica.

[65]  P. Mbaya,et al.  Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder , 2007, Human psychopharmacology.

[66]  J. López-Ibor,et al.  What can be learnt from the natural history of anxiety disorders? , 2007, European Psychiatry.

[67]  J. Rogers,et al.  Psychiatric comorbidity following traumatic brain injury , 2007, Brain injury.

[68]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia , 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[69]  A. Prange,et al.  Psychiatric Manifestations of Graves’ Hyperthyroidism , 2006, CNS drugs.

[70]  J. Hellings,et al.  Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents , 2006, Clinical drug investigation.

[71]  J. Savarino,et al.  Suicide risk during antidepressant treatment. , 2006, The American journal of psychiatry.

[72]  H. Wittchen,et al.  Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies , 2005, European Neuropsychopharmacology.

[73]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[74]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[75]  L. Scahill,et al.  The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. , 2005, Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc.

[76]  D. Nutt Death by tricyclic: the real antidepressant scandal? , 2005, Journal of psychopharmacology.

[77]  J. Januzzi,et al.  The High Prevalence of Multiple Psychiatric Disorders in Stable Outpatients With Coronary Heart Disease , 2004, Psychosomatic medicine.

[78]  Maria G. Tanzi,et al.  Paradoxical Reactions to Benzodiazepines: Literature Review and Treatment Options , 2004, Pharmacotherapy.

[79]  J. Lépine,et al.  The European Study of the Epidemiology of Mental Disorders (ESEMeD) project: an epidemiological basis for informing mental health policies in Europe , 2004, Acta psychiatrica Scandinavica. Supplementum.

[80]  F. Mazzi,et al.  Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.

[81]  D. Nutt,et al.  Treatment of anxiety and depressive disorders in patients with cardiovascular disease , 2004, BMJ : British Medical Journal.

[82]  C. Pisinger,et al.  Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review , 2004, Nordic journal of psychiatry.

[83]  N. Simon,et al.  Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder , 2003, Journal of psychopharmacology.

[84]  S. Čavaljuga,et al.  Clomipramine and fluoxetine effects in the treatment of panic disorder. , 2003, Bosnian journal of basic medical sciences.

[85]  M. Otto,et al.  Treating Medication-Resistant Panic Disorder: Predictors and Outcome of Cognitive-Behavior Therapy in a Brazilian Public Hospital , 2002, Psychotherapy and Psychosomatics.

[86]  R. Califf,et al.  Sertraline treatment of major depression in patients with acute MI or unstable angina , 2002, European Neuropsychopharmacology.

[87]  Dan J Stein,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[88]  R A Gould,et al.  An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. , 2001, The American journal of psychiatry.

[89]  E. Rüther,et al.  Separation Anxiety and Actual Separation Experiences during Childhood in Patients with Panic Disorder , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[90]  S. Woods,et al.  Early coadministration of clonazepam with sertraline for panic disorder. , 2001, Archives of general psychiatry.

[91]  E. Smeraldi,et al.  A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study , 2001, Pharmacopsychiatry.

[92]  D. A. Spiegel Psychological strategies for discontinuing benzodiazepine treatment. , 1999, Journal of clinical psychopharmacology.

[93]  J. Carlson,et al.  Sertraline treatment of 5 children diagnosed with selective mutism: a single-case research trial. , 1999, Journal of child and adolescent psychopharmacology.

[94]  U. Lepola,et al.  The effect of Citalopram in panic disorder , 1997, British Journal of Psychiatry.

[95]  Y. Lecrubier,et al.  Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder , 1997 .

[96]  C. Gillberg,et al.  Selective mutism: a population-based study: a research note. , 1997, Journal of child psychology and psychiatry, and allied disciplines.

[97]  R. Daroff,et al.  Clinical Handbook of Psychotropic Drugs , 1994 .

[98]  E. Sellers,et al.  Clinical aspects of chronic use of alprazolam and lorazepam. , 1995, The American journal of psychiatry.

[99]  W. Boyer Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta‐analysis , 1995, International clinical psychopharmacology.

[100]  B Black,et al.  Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[101]  A. Bystritsky,et al.  Double-blind pilot trial of desipramine versus fluoxetine in panic patients. , 1994, Anxiety.

[102]  J. Rosenbaum,et al.  Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. , 1993, The American journal of psychiatry.

[103]  J. Rosenbaum,et al.  Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. , 1993, Journal of clinical psychopharmacology.

[104]  F. Goodwin,et al.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. , 1993, Archives of general psychiatry.

[105]  M. Mavissakalian,et al.  Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. , 1992, Archives of general psychiatry.

[106]  G. Klerman,et al.  Drug Treatment of Panic Disorder: Comparative Efficacy of Alprazolam, Imipramine, and Placebo , 1992, British Journal of Psychiatry.

[107]  S. Woods,et al.  Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. , 1992, Journal of clinical psychopharmacology.

[108]  H. Koplewicz,et al.  Imipramine treatment of children with separation anxiety disorder. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[109]  P. Bech,et al.  Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study , 1991, Acta psychiatrica Scandinavica. Supplementum.

[110]  D. Greenblatt,et al.  Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. , 1990, Archives of general psychiatry.

[111]  P. Riekkinen,et al.  Clinical evaluation of alprazolam in patients with panic disorder: A double‐blind comparison with imipramine , 1990 .

[112]  W. Agras,et al.  Cardiovascular and Symptomatic Reduction Effects of Alprazolam and Imipramine in Patients with Panic Disorder: Results of a Double-Blind, Placebo-Controlled Trial , 1990, Journal of clinical psychopharmacology.

[113]  R. Glass,et al.  Response of panic disorder to fixed doses of alprazolam or imipramine. , 1989, Journal of affective disorders.

[114]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. , 1989, Archives of general psychiatry.

[115]  S. Woods,et al.  Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. , 1989, Archives of general psychiatry.

[116]  T. Silverstone,et al.  Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline. , 1988 .

[117]  K. Rickels Benzodiazepines in the treatment of anxiety. , 1982, American journal of psychotherapy.

[118]  Jacob Cohen,et al.  The statistical power of abnormal-social psychological research: a review. , 1962, Journal of abnormal and social psychology.

[119]  M. Hamilton The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.